-
Mashup Score: 2Video Insights | Blood Cancers Today - 4 month(s) ago
Watch expert interviews from leading hematologists and oncologists on Blood Cancers Today.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Linvoseltamab Now Under FDA Review as a Potential Treatment Option for RRMM | Blood Cancers Today - 4 month(s) ago
The FDA has accepted a BLA for linvoseltamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The FDA has accepted a BLA for linvoseltamab for R/R myeloma in the fourth-line setting or for patients who are in the third-line setting and are refractory to the last line of therapy. Read more about the approval, with insight from @JoshuaRichterMD. ➡️ https://t.co/Ft05VJvb7W https://t.co/iA7Qu4ZbOt
-
-
Mashup Score: 11Natalie Callander, MD, on Selinexor in Myeloma: Triplet Combinations, Dosing, Efficacy | Blood Cancers Today - 4 month(s) ago
Natalie Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
We recently spoke with @nsc_natalie, of @UWCarbone, on selinexor, pomalidomide, and dexamethasone for the treatment of relapsed or refractory multiple #myeloma. 📺 Watch here! https://t.co/6VHTA7uyUo https://t.co/n2ViQ871Iv
-
-
Mashup Score: 2Olutasidenib and Azacitidine Combination Expands Options for mIDH1 Relapsed or Refractory AML | Blood Cancers Today - 4 month(s) ago
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant #AML treated with the experimental combination of olutasidenib and azacitidine, according to a study led by @GCC_Cortes of @GACancerCenter. 📰 Read more: https://t.co/H2s214uvEf https://t.co/kLaY4S0xH9
-
-
Mashup Score: 2TREATT Trial Evaluates Tranexamic Acid for Bleeding Prevention in Hematologic Malignancies | Blood Cancers Today - 4 month(s) ago
Compared with placebo, tranexamic acid did not reduce bleeding in patients with hematologic malignancies and severe thrombocytopenia undergoing intensive chemotherapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📝 The TREATT trial published in @TheLancetHaem evaluated the use of tranexamic acid for bleeding prevention in patients with hematologic malignancies and severe thrombocytopenia undergoing intensive chemotherapy. 📰 Read more: https://t.co/4WerPCPnaM https://t.co/ZKHk78W0eR
-
-
Mashup Score: 8Optimizing MDS Management: Key Takeaways from the COMMANDS Trial | Blood Cancers Today - 4 month(s) ago
Thomas LeBlanc, MD, MA; Andrew Brunner, MD; and Jamie Koprivnikar, MD, discuss the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
At this #ASH24 roundtable, @tomleblancMD (@DukeCancer), @andrewbrunner (@MassGeneralNews), and Jamie Koprivnikar, (@JTCancerCenter), discuss key takeaways from the COMMANDS trial in #MDS. Watch now ➡️ https://t.co/ZGQzHWL2go https://t.co/0MBHvSzN8g
-
-
Mashup Score: 1
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1% and a CR rate of 94.2%.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
The European Medicines Agency's CHMP has recommended approval of liso-cel for the treatment of adult patients with relapsed or refractory follicular #lymphoma who have received two or more prior lines of therapy, according to @bmsnews. 📰 Read more: https://t.co/qwCVO5ExZ3 https://t.co/lPye9HjAZ8
-
-
Mashup Score: 1Benefits of Pirtobrutinib Treatment in Patients With Chronic Lymphocytic Leukemia | Blood Cancers Today - 4 month(s) ago
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib in heavily pretreated patients with relapsed or refractory CLL/SLL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🙌 @jeff_sharman, of @TheUSONetwork, discusses pivotal findings from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib in heavily pretreated patients with relapsed or refractory #CLL and #SLL. 📺 Watch here! https://t.co/KbVR6IwfJt https://t.co/cyxbrx2kXD
-
-
Mashup Score: 1Comparing Risk Scores for Disease Progression in Untreated CLL | Blood Cancers Today - 4 month(s) ago
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores categorized 34.4% of patients with untreated CLL in the same risk category.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A recent study compared the accuracy of five risk scores to predict disease progression in patients with untreated #CLL and found that a certain IGHV subset can improve the accuracy of the risk scores. 📰 Read more: https://t.co/O74cGYEaw7 https://t.co/RuLMMj1KcQ
-
-
Mashup Score: 4Genetics of High-Altitude Population Correlated With Better Response to Treatment for MPNs | Blood Cancers Today - 4 month(s) ago
A new study has identified genetic factors that can affect the molecular pathways involved in treatment response among patients with MPNs.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🧬 A study identified genetic variants common among the Aymara Indigenous community in the Andean mountains that are correlated with a better response to ropeginterferon-α, a drug used to treat polycythemia vera and essential thrombocythemia. 📰 https://t.co/eQDzqcMQsk https://t.co/IH9oB8nywG
-
TGIF 😍 If you're looking for something to do this weekend, why not catch up on our video interviews? @TaylorJ_MD, @SanjayPatelMD, @paurotero, @leshune, and other experts discuss all the latest in #multiplemyeloma, #CLL, and more! 📺 https://t.co/jvcKJQ9DD7 https://t.co/OU6Ek5qp0U